Oncology (all articles)
Review | Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
29 May, 2023 | 11:08h | UTCMitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
In a Review now published online, @maryam_lustberg @NicoleKuderer @ADesaiMD @crisbergerot and @gary_lyman discuss the mitigation of long-term toxicities from cancer treatment, including financial toxicity and psychosocial needs: https://t.co/Gu08RtT0nO pic.twitter.com/OX9tUZyuY5
— NatureRevClinOncol (@NatRevClinOncol) May 25, 2023
MASCC Guidelines for the prevention and management of acute radiation dermatitis | Part 1 – Systematic review
29 May, 2023 | 10:53h | UTCRelated:
RCT | Bacterial decolonization for prevention of radiation dermatitis
RCT | Mepitel film for the prevention of acute radiation dermatitis in breast cancer.
SR | Management of lymph node–positive penile cancer
24 May, 2023 | 13:03h | UTCManagement of Lymph Node–positive Penile Cancer: A Systematic Review – European Urology
USPSTF Draft Statement recommends biennial screening mammography for women ages 40 to 74 years
22 May, 2023 | 13:56h | UTCBreast Cancer: Screening – U.S. Preventive Services Task Force
Critical perspectives on the statement:
Earlier screening for breast cancer: Benefits and harms – Lown Institute
Why more mammograms aren’t the solution to breast cancer – Vox
Review | Cholangiocarcinoma — novel biological insights and therapeutic strategies
22 May, 2023 | 13:38h | UTC
Commentary on Twitter
In a new Review, Greg Gores & co. discuss advances in cholangiocarcinoma over the past 5 yrs, focusing on the immune TME, CAFs, molecular diagnostics & classifications, target therapy, immunotherapy & transplantation:https://t.co/f4BYxY69tk #hpbcsm #medonc #camoldx #camicroenv pic.twitter.com/lqmwgp9hxh
— NatureRevClinOncol (@NatRevClinOncol) May 16, 2023
ASCO Guideline Update | ESR1 mutation testing for HR+/HER2- metastatic breast cancer therapy
22 May, 2023 | 13:27h | UTC
Epidemiology of bladder cancer in 2023: a systematic review of risk factors
22 May, 2023 | 13:23h | UTCEpidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors – European Urology
Review | Hereditary colorectal, gastric, and pancreatic cancer
18 May, 2023 | 13:43h | UTCHereditary colorectal, gastric, and pancreatic cancer: comprehensive review – BJS Open
Commentary on Twitter
Have a🔎at our latest comprehensive review covering all u need to know📜about hereditary 🧬colorectal, gastric & pancreatic🦀! https://t.co/y1LL0DNRiy@Adductor @DrRABurkhart #SoMe4Surgery #StepUp4CRC #SurgEd #MedTwitter @BJSAcademy @BJSurgery @juliomayol @young_bjs Great read! pic.twitter.com/JmmOmMBydO
— BJS Open (@BjsOpen) May 11, 2023
RCT | Cabozantinib addition to nivolumab and ipilimumab extends progression-free survival in renal-cell carcinoma
18 May, 2023 | 13:38h | UTCCabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Cabozantinib in Renal-Cell Carcinoma – NEJM Resident 360
Commentary on Twitter
Clinical Pearls & Morning Reports: Cabozantinib in Renal-Cell Carcinoma. How did the addition of cabozantinib to nivolumab and ipilimumab affect outcomes in the trial by Choueiri et al.? https://t.co/x1FzWBiasr #MedEd #MedTwitter pic.twitter.com/w4sns1ifLG
— NEJM Resident 360 (@NEJMres360) May 16, 2023
Current perioperative care in pancreatoduodenectomy: a step-by-step surgical roadmap from first visit to discharge
16 May, 2023 | 14:52h | UTC
Commentary on Twitter
Step by step surgical roadmap 🗺️ for pancreatoduodenectomy
🧭 Pre, intra and post operative periods have specific landmarks
⚖️ Such factors weight the actual value of surgery vs. alternative options
🔑 is minimize complications and patients selectionhttps://t.co/3obsQdfHs6 pic.twitter.com/6EHoRjc2wE
— Giovanni Marchegiani (@Gio_Marchegiani) April 27, 2023
Cohort Study | 5-mm margins may be adequate for T1a melanoma excision near critical structures
16 May, 2023 | 14:40h | UTCAssociation of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures – JAMA Dermatology (link to abstract – $ for full-text)
Commentary: Melanoma Excisions with 5 Millimeter Margins Linked to Less Risk of Local Recurrence – HCP Live
Commentary on Twitter
Study on thin melanomas (T1a) near critical anatomic sites such as the head and face showed that 5-mm surgical margins may be safe for patients and decrease reconstructive surgery and potential adverse, including scarring and mental issues. https://t.co/Mw7Ub4xMVX
— JAMA Dermatology (@JAMADerm) April 12, 2023
Towards precision pain medicine for pain after cancer: guidelines for pain phenotyping using nociplastic pain criteria
16 May, 2023 | 14:35h | UTC
Commentary on Twitter
Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria https://t.co/SLTPMzHZwE pic.twitter.com/RTpaARWuAa
— Physio Meets Science (@PhysioMeScience) January 27, 2023
Article under a Creative Commons (CC BY-NC-ND 4.0) license
RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases
16 May, 2023 | 14:30h | UTC
Commentary on Twitter
RCT: In patients with untreated EGFR-mutated non-small cell lung cancer with brain metastases, gefitinib + chemo improved survival and PFS vs gefitinib, with manageable adverse events, and may be a viable first-line treatment. #NSCLC https://t.co/Oe6zHYVsPV pic.twitter.com/oUvs12pYS7
— JAMA Network Open (@JAMANetworkOpen) February 9, 2023
Clinical Trial Update | Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer
16 May, 2023 | 14:25h | UTCCommentaries:
Original Study: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer – New England Journal of Medicine
An update on the role of immunohistochemistry in the evaluation of pancreatic/liver/gastrointestinal luminal tract disorders
15 May, 2023 | 13:02h | UTC
2023 Rectal cancer lexicon update | Revised consensus on terminology and staging
15 May, 2023 | 12:50h | UTC
Cohort Study | Following lifestyle recommendations linked to lower recurrence in high-risk breast cancer
15 May, 2023 | 12:48h | UTCCommentary: Adherence to healthy lifestyle found to cut breast cancer recurrence, mortality – HealthDay
Commentary on Twitter
Adherence to the @AmericanCancer and the @aicrtweets lifestyle recommendations before and after high-risk breast cancer treatment was associated with a 37% reduced risk of disease recurrence and a 58% reduction in mortality. https://t.co/sy6b8CGgr1
— JAMA Network Open (@JAMANetworkOpen) May 4, 2023
Post-pneumonectomy syndrome: a systematic review of the current evidence and treatment options
15 May, 2023 | 12:45h | UTC
Clinical Trial Update | Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer
15 May, 2023 | 12:43h | UTCOriginal Article: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer – New England Journal of Medicine
Endocrinopathies from checkpoint inhibitors: incidence, outcomes, and management
12 May, 2023 | 13:36h | UTCRelated:
Cohort Study | Outcomes of surgery in cardiac angiosarcoma
12 May, 2023 | 13:35h | UTC
Commentary on Twitter
A study in #JACCCardioOnc from US national cancer database identifies 239 patients w/ rare cardiac tumor angiosarcoma:
🔸 Surgery is underutilized
🔸 Higher income, recentness of Dx, early stage, use of surgery, & #chemotherapy had a better outcome— JACC Journals (@JACCJournals) May 6, 2023
M-A | First‐line therapy for adults with advanced renal cell carcinoma
12 May, 2023 | 13:33h | UTCSummary: Initial treatment for adults with advanced kidney cancer (renal cell carcinoma) – Cochrane Library
RCT | Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma
12 May, 2023 | 13:18h | UTCNews Release: ChemoID platform-predicted treatments lead to longer survival for glioblastoma patients – University of Cincinnati
Commentary on Twitter
Online now: Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial https://t.co/y5GYCCgg3b
— Cell Reports Medicine (@CellRepMed) May 3, 2023
Uncertainties and controversies in axillary management of patients with breast cancer
11 May, 2023 | 11:53h | UTC
Neurosurgical interventions for cerebral metastases of solid tumors
11 May, 2023 | 11:48h | UTC